Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes

BACKGROUND: We assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 mg and lixisenatide 20 μg (both added to basal insulin) in patients with type 2 diabetes (T2D) in Sweden. METHODS: The Swedish Institute for Health Economics cohort model for T2D was used...

Descripción completa

Detalles Bibliográficos
Autores principales: Ericsson, Åsa, Glah, Divina, Lorenzi, Maria, Jansen, Jeroen P., Fridhammar, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800677/
https://www.ncbi.nlm.nih.gov/pubmed/29408938
http://dx.doi.org/10.1371/journal.pone.0191953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800677/
https://www.ncbi.nlm.nih.gov/pubmed/29408938
http://dx.doi.org/10.1371/journal.pone.0191953

Ejemplares similares